The modern diet has seen a drastic reduction in the intake of omega-3 fatty acids, compounded by a significantly greater intake of omega-6 fatty acids. This is problematic as many of our tissues rely on fatty acids for proper synthesis and communication. If the appropriate fatty acids are not available, the implications for overall health are serious. Ultimately, a relative deficiency of omega-3 fatty acids can lead to a pro-inflammatory state and increase the risk of chronic disease. 

The active compounds responsible for the widespread benefits of fish oil supplementation have been identified as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Although both are important for various aspects of human health, EPA is generally regarded as the anti-inflammatory fatty acid while DHA is more responsible for neurodevelopment and nerve protection.

EPA and DHA have been clinically studied in a variety of health conditions. For example, supplementation with these omega-3 fatty acids have been found to be beneficial for maintaining cardiovascular health, rheumatoid arthritis, autoimmunity, cognition, mood, skin health and atopic concerns, to name just a few clinical indications. Simply put, EPA and DHA should be considered for any systemic inflammatory condition.

One challenge that arises with omega-3 fatty acid supplementation is poor compliance. Most supplements require many capsules or teaspoons per day to achieve an evidence-based dose of EPA and DHA. Cyto·Matrix’s Peak·EPA solves this problem by providing 700mg of EPA and 350mg of DHA in a single softgel. These omega-3 fatty acids, sourced from wild deep sea fish, are found in the well-researched ethyl ester form, allowing for evidence-based, extremely concentrated and cost-effective delivery.

Peak·EPA is molecularly distilled, ensuring purity and removal of harmful compounds such as heavy metals and organophosphates. Vitamin E is added to the formula to protect against and prevent oxidation.

Available in 90 and 180 softgel bottles.